Saniona AB (SANION) - Net Assets

Latest as of December 2025: Skr635.16 Million SEK ≈ $68.35 Million USD

Based on the latest financial reports, Saniona AB (SANION) has net assets worth Skr635.16 Million SEK (≈ $68.35 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr679.74 Million ≈ $73.15 Million USD) and total liabilities (Skr44.58 Million ≈ $4.80 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Saniona AB liquidity resilience to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets Skr635.16 Million
% of Total Assets 93.44%
Annual Growth Rate N/A
5-Year Change 125.23%
10-Year Change 1070.76%
Growth Volatility 478.38

Saniona AB - Net Assets Trend (2012–2025)

This chart illustrates how Saniona AB's net assets have evolved over time, based on quarterly financial data. Also explore Saniona AB balance sheet assets for the complete picture of this company's asset base.

Annual Net Assets for Saniona AB (2012–2025)

The table below shows the annual net assets of Saniona AB from 2012 to 2025. For live valuation and market cap data, see SANION company net worth.

Year Net Assets Change
2025-12-31 Skr635.16 Million
≈ $68.35 Million
+173.99%
2024-12-31 Skr231.82 Million
≈ $24.95 Million
+1156.60%
2023-12-31 Skr-21.94 Million
≈ $-2.36 Million
-141.63%
2022-12-31 Skr52.71 Million
≈ $5.67 Million
-81.31%
2021-12-31 Skr282.00 Million
≈ $30.35 Million
-53.27%
2020-12-31 Skr603.46 Million
≈ $64.94 Million
+932.66%
2019-12-31 Skr58.44 Million
≈ $6.29 Million
+48.10%
2018-12-31 Skr39.46 Million
≈ $4.25 Million
+4.86%
2017-12-31 Skr37.63 Million
≈ $4.05 Million
-30.64%
2016-12-31 Skr54.25 Million
≈ $5.84 Million
+2.47%
2015-12-31 Skr52.94 Million
≈ $5.70 Million
+502.93%
2014-12-31 Skr8.78 Million
≈ $944.98K
+1427.13%
2013-12-31 Skr575.00K
≈ $61.88K
+137.31%
2012-12-31 Skr-1.54 Million
≈ $-165.84K
--

Equity Component Analysis

This analysis shows how different components contribute to Saniona AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 35084600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Common Stock Skr6.90 Million 1.09%
Other Comprehensive Income Skr-19.75 Million -3.11%
Other Components Skr1.00 Billion 157.53%
Total Equity Skr635.16 Million 100.00%

Saniona AB Competitors by Market Cap

The table below lists competitors of Saniona AB ranked by their market capitalization.

Company Market Cap
TYM Corporation
KO:002900
$207.74 Million
Brogent Technologies
TWO:5263
$207.84 Million
Pitanium Ltd
NASDAQ:PTNM
$207.93 Million
Halma PLC
LSE:HLMA
$208.04 Million
Mayfield Group Holdings Ltd
AU:MYG
$207.53 Million
Avalue Technology
TWO:3479
$207.33 Million
Triplepoint Venture Growth BDC Corp
NYSE:TPVG
$207.31 Million
Kaltura Inc
NASDAQ:KLTR
$207.16 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Saniona AB's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 231,818,000 to 635,159,000, a change of 403,341,000 (174.0%).
  • Net income of 284,666,000 contributed positively to equity growth.
  • New share issuances of 114,951,000 increased equity.
  • Other comprehensive income decreased equity by 26,956,000.
  • Other factors increased equity by 30,680,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income Skr284.67 Million +44.82%
Share Issuances Skr114.95 Million +18.1%
Other Comprehensive Income Skr-26.96 Million -4.24%
Other Changes Skr30.68 Million +4.83%
Total Change Skr- 173.99%

Book Value vs Market Value Analysis

This analysis compares Saniona AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 2.91x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2012-12-31 Skr-0.11 Skr13.98 x
2013-12-31 Skr0.04 Skr13.98 x
2014-12-31 Skr0.65 Skr13.98 x
2015-12-31 Skr2.90 Skr13.98 x
2016-12-31 Skr2.53 Skr13.98 x
2017-12-31 Skr1.71 Skr13.98 x
2018-12-31 Skr1.77 Skr13.98 x
2019-12-31 Skr1.92 Skr13.98 x
2020-12-31 Skr12.45 Skr13.98 x
2021-12-31 Skr3.82 Skr13.98 x
2022-12-31 Skr0.71 Skr13.98 x
2023-12-31 Skr-0.34 Skr13.98 x
2024-12-31 Skr2.16 Skr13.98 x
2025-12-31 Skr4.80 Skr13.98 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Saniona AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 44.82%
  • The company demonstrates strong efficiency in generating profits from shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 65.53%
  • • Asset Turnover: 0.64x
  • • Equity Multiplier: 1.07x
  • Recent ROE (44.82%) is above the historical average (-85.17%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2012 0.00% -21.30% 0.97x 0.00x Skr-1.50 Million
2013 -224.25% -9.45% 0.91x 26.21x Skr-1.35 Million
2014 -67.28% -27.20% 1.40x 1.76x Skr-6.79 Million
2015 -43.34% -168.36% 0.24x 1.09x Skr-28.24 Million
2016 4.09% 2.96% 1.06x 1.30x Skr-3.21 Million
2017 -130.72% -237.72% 0.43x 1.29x Skr-52.95 Million
2018 -104.06% -74.81% 0.66x 2.11x Skr-45.00 Million
2019 -129.69% -2851.32% 0.03x 1.64x Skr-81.63 Million
2020 -12.17% -895.71% 0.01x 1.15x Skr-133.78 Million
2021 -145.71% -3921.53% 0.02x 1.56x Skr-439.10 Million
2022 -465.50% -1605.42% 0.10x 2.92x Skr-250.63 Million
2023 0.00% -568.94% 0.26x 0.00x Skr-93.62 Million
2024 81.40% 56.39% 0.99x 1.47x Skr165.52 Million
2025 44.82% 65.53% 0.64x 1.07x Skr221.15 Million

Industry Comparison

This section compares Saniona AB's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $181,930,027
  • Average return on equity (ROE) among peers: -108.15%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Saniona AB (SANION) Skr635.16 Million 0.00% 0.07x $207.66 Million
2cureX AB (2CUREX) $8.19 Million -5.85% 0.47x $4.90 Million
Ascelia Pharma AB (publ) (ACE) $236.06 Million -41.81% 0.08x $40.96 Million
AcouSort AB (ACOU) $5.92 Million -163.51% 0.36x $8.97 Million
Active Biotech AB (ACTI) $30.67 Million -149.35% 0.44x $17.19 Million
Alzinova AB (ALZ) $947.42K -195.83% 0.18x $4.97 Million
AlzeCure Pharma (ALZCUR) $32.97 Million -235.89% 0.38x $18.18 Million
Annexin Pharmaceuticals AB (ANNX) $18.81 Million -234.16% 0.42x $11.24 Million
Alligator Bioscience AB (ATORX) $115.24 Million -124.61% 0.32x $14.33 Million
BioInvent International AB (BINV) $1.31 Billion -25.22% 0.07x $155.44 Million
BioArctic AB (publ) (BIOA-B) $60.76 Million 94.77% 10.65x $2.59 Billion

About Saniona AB

ST:SANION Sweden Biotechnology
Market Cap
$207.66 Million
Skr1.93 Billion SEK
Market Cap Rank
#16398 Global
#266 in Sweden
Share Price
Skr13.98
Change (1 day)
-0.57%
52-Week Range
Skr7.92 - Skr27.50
All Time High
Skr52.03
About

Saniona AB (publ), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company's product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical t… Read more